Stereotaxis reported Q2 Revenue of $7.7 million and EPS of $‑0.05, exactly matching analyst expectations. The result shows continued operating loss, with a $4.5 million net deficit, signaling cash‑flow pressure but a clear for shareholders path toward profitability later in 2027.
Key Highlights
- Operating expenses totaled $9.1 million; cash on hand $10.5 million, no debt
- Stereotaxis reported $7.7 million in revenue and a net loss of $4.5 million for the quarter ended June 30, 2026, with EPS of -$0.05.
- Quarterly system sales halved to $1.5 million from $3.0 million in the prior year, partially offset by the launch of Synchrony system sales.
- Recurring revenue surged 270% sequentially to $6.2 million, demonstrating traction in the company's core recurring business.
Stereotaxis (NYSE American: STXS) delivered $7.7 million of revenue for the quarter ended June 30, 2026, and posted Earnings Per Share of $‑0.05, precisely in line with consensus forecasts. The company recorded a net loss of $4.5 million, widening the gap between operating cash outflows and earnings.
Q2 Revenue and EPS Detail
The quarter’s Top Line of $7.7 million split between $1.5 million in system sales and $6.2 million in recurring revenue. System revenue halved from the prior‑year level of $3.0 million, a shortfall partially offset by the launch of Synchrony system sales. Recurring Revenue climbed 270% sequentially, crossing the $1 million threshold for robotic catheters and lifting total recurring sales to $6.2 million.
Gross Margin for the period stood at 58% of revenue, with recurring streams delivering a 66% margin versus a 29% margin on system sales. These figures suggest the company’s core recurring Business is gaining traction even as new system deliveries lag.
Cost Structure and Cash Position
Operating expenses reached $9.1 million, including $2.5 million of non‑cash charges for stock compensation, contingent earn‑out adjustments, and intangible amortization. Stripping those items left adjusted operating expenses of $6.6 million, unchanged from the comparable prior period when a one‑time tax Credit was recorded.
Market Reaction and Outlook
System revenue is expected to stabilize around $3 million per quarter, a significant uplift from the current $1.5 million level. Management believes cash‑flow profitability will materialize in the first half of 2027, a timeline that, if met, could catalyze a Revaluation of the stock given its current market cap of $141 million.
Forward Catalyst
Stereotaxis will detail its progress toward the $3 million system revenue target and cash‑flow breakeven in its upcoming quarterly report, offering investors a chance to assess whether the revenue acceleration plans are on track.






Please wait processing your request...